Abstract
Aim: To develop novel anti-breast cancer agents and discuss the structure-activity relationship of bis-isatin scaffolds.
Background: Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women after lung cancer. Bis-isatin scaffolds possess potential anti-breast cancer activity, and some of them such as Indirubin could induce cancer cells apoptosis via multiply mechanisms.
Objective: The primary objective of this study was to evaluate the potential of bis-isatin scaffolds with alkyl/ether linkers between the two isatin moieties against different human breast cancer cell lines including MCF-7, AU565, MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells.
Methods: The synthesized bis-isatin scaffolds with alkyl/ether linker between the two isatin moieties were evaluated for their in vitro activity against MCF-7, AU565, MDA-MB-231, MDA-MB-435, and MDA-MB-468 human breast cancer cell lines by MTT assay.
Results: All the synthesized compounds (IC50: 38.3-197.6 µM) possess considerable activity against MCF-7, AU565, MDA-MB-231, MDA-MB-435, and MDA-MB-468 human breast cancer cell lines, and the most potent compound 4e (IC50: 38.3-63.5 µM) was no inferior to Cisplatin (IC50: 20.1-38.6 μM) against the five tested human breast cancer cell lines.
Conclusion: All the synthesized bis-isatin scaffolds were active against a panel of breast cancer cell lines, highlighting the significance of exploring the bis-isatin scaffolds to fight against breast cancers. The enriched structure-activity relationship may set up the direction for the rational design and development of novel bis-isatin scaffolds with higher efficiency.
Keywords: Bis-isatin, Breast cancer, Structure-activity relationships, Alkyl/ether linkers, Cisplatin, Nintedanib.
Graphical Abstract
[http://dx.doi.org/10.3322/caac.21412] [PMID: 28972651]
[http://dx.doi.org/10.1016/j.mpmed.2019.11.009]
[http://dx.doi.org/10.1016/j.semcancer.2019.12.016] [PMID: 31870940]
[http://dx.doi.org/10.1016/j.hoc.2013.05.011] [PMID: 23915747]
[http://dx.doi.org/10.2174/1381612825666190712183436] [PMID: 31309884]
[http://dx.doi.org/10.2174/157340809789630271]
[http://dx.doi.org/10.1016/j.bionut.2013.04.001]
[PMID: 29243578]
[http://dx.doi.org/10.1002/ardp.201900367] [PMID: 31960987]
[http://dx.doi.org/10.1016/j.bmcl.2016.02.015] [PMID: 26883150]
[http://dx.doi.org/10.2174/187152008785914743] [PMID: 18855582]
[http://dx.doi.org/10.1021/acs.jmedchem.5b01380] [PMID: 27010926]
[http://dx.doi.org/10.2174/1568026618666180221114515] [PMID: 29473509]
[http://dx.doi.org/10.1016/j.ejmech.2013.04.040] [PMID: 24176732]
[http://dx.doi.org/10.1002/jhet.3410]
[http://dx.doi.org/10.1002/ardp.201900299] [PMID: 31985855]
[http://dx.doi.org/10.2147/DDDT.S174613] [PMID: 30323565]
[http://dx.doi.org/10.1002/jhet.3330]
[http://dx.doi.org/10.1016/j.ejmech.2012.06.057] [PMID: 22818042]
[http://dx.doi.org/10.1002/slct.201800420]
[http://dx.doi.org/10.1016/j.ejmech.2012.10.008] [PMID: 23124212]
[http://dx.doi.org/10.1002/jhet.3781]
[http://dx.doi.org/10.1002/jhet.3691]
[http://dx.doi.org/10.1016/j.fitote.2018.03.018] [PMID: 29631015]
[http://dx.doi.org/10.1002/jhet.3255]
[http://dx.doi.org/10.1002/jhet.3554]
[http://dx.doi.org/10.2174/1568026619666190806151401] [PMID: 31385773]